This study is primarily designed to assess the safety and the tolerability of Debio1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 genes, for whom standard treatment does not exist or is not indicated. The main objective of Part A is to identify the dose-limiting toxicities (DLTs) and estimate the maximum tolerated dose (MTD) based on the safety and tolerability of Debio1347 orally administered daily to these patients, in order to determine the recommended dose. The main objective of Part B is to evaluate the safety profile at the recommended dose, in a larger cohort of these patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part A: Percentage of Participants With Dose-Limiting Toxicities (DLTs) From Debio 1347
Timeframe: within approximately 18 months
Part B: Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)
Timeframe: within 2 years of starting treatment
Part B: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
Timeframe: within 2 years of starting treatment
Part B: Severity of Treatment-Emergent AEs
Timeframe: within 2 years of starting treatment
Part B: Severity of Laboratory Abnormalities
Timeframe: within 2 years of starting treatment